Nanomedicine-based Chemo-Immunotherapy for the Treatment of Pediatric Brain Cancer

2023 年度 実施状況報告書

• 研究課題/領域番号: 22K12833
• 研究機関: 公益財団法人川崎市産業振興財団(ナノ医療イノベーションセンター)
• 研究代表者: 劉 学瑩 公益財団法人川崎市産業振興財団(ナノ医療イノベーションセンター), ナノ医療イノベーションセンター, 主任研究員 (30777470)
• 研究分担者: 喜納 宏昭 公益財団法人川崎市産業振興財団(ナノ医療イノベーションセンター), ナノ医療イノベーションセンター, 主幹研究員 (70283067) ; Quader Sabina 公益財団法人川崎市産業振興財団(ナノ医療イノベーションセンター), ナノ医療イノベーションセンター, 副主幹研究員 (90749699)
• 研究期間 (年度): 2022-04-01 – 2025-03-31
• キーワード: Nanomedicine / ICIs / medulloblastoma

研究実績の概要

We have successfully developed and confirmed the effectiveness of a syngeneic mouse model for medulloblastoma, a type of brain tumor in our laboratory.
In our research, we have conducted extensive screenings of multiple anticancer drug-loaded nanomedicines against this model, leading to significant findings.
Furthermore, we have also conducted screenings of several immune checkpoint inhibitors (PD1, PDL1, CTLA-4, CD47, CD24, CD276) against the MB syngeneic model, resulting in important and promising research outcomes.

現在までの達成度 (区分)

2: おおむね順調に進展している

理由

A substantial amount of research-related data has been collected.

今後の研究の推進方策

Confirmation of synergistic or combination effect of anticancer drug-loaded nanomedicine and immune checkpoint inhibitors. Additionally, intellectual patent filing and dissemination of results through conference presentation and journal article publication.

次年度使用額が生じた理由

Due to other important commitments, it was not possible to attend the planned international conferences, which have been rescheduled for this fiscal year.

研究成果

• [雑誌論文] Identifying molecular tags selectively retained on the surface of brain endothelial cells to generate artificial targets for therapy delivery. (2023)
  • 著者名/発表者名: 48.G. M. Porro, I. Lorandi, X. Liu, K. Kataoka, G. Battaglia, D. G.-Carter,
  • 雑誌名: Fluids Barriers CNS 巻: 20 ページ: 88
  • DOI: 10.1186/s12987-023-00493-6